Zoubida Karim

Prof. Zoubida Karim

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Gastroenterology
Verified
Journal Article
Closed access
CBCarole Brasse-Lagnel
Carole Brasse-Lagnel
Zoubida KarimZoubida Karim
Zoubida Karim
PLPhilippe Letteron
Philippe Letteron
SBSoumeya Bekri
Soumeya Bekri
ABAndré Bado
André Bado
CBCarole Beaumont
Carole Beaumont

1 September 2015 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
Zoubida KarimZoubida Karim
Zoubida Karim
SLSaid Lyoumi
Said Lyoumi
GAËL NICOLASGAËL NICOLAS
GAËL NICOLAS
JDJean-Charles Deybach
Jean-Charles Deybach
LGLaurent Gouya
Laurent Gouya
HPHervé Puy
Hervé Puy

1 July 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MHMing Chang Hu
Ming Chang Hu
LFLingzhi Fan
Lingzhi Fan
LCLadonna A. Crowder
Ladonna A. Crowder
Zoubida KarimZoubida Karim
Zoubida Karim
HMHeini Murer
Heini Murer
OMOrson W. Moe
Orson W. Moe
Dopamine (DA) is a key hormone in mammalian sodium homeostasis. DA induces natriuresis via acute inhibition of the renal proximal tubule apical membrane Na(+)/H(+) exchanger NHE3. We examined the mechanism by which DA inhibits NHE3 in a renal cell line. DA acutely decreases surface NHE3 antigen in dose- and time-dependent fashion without altering total cellular NHE3. Although DA(1) receptor agonist alone decreases surface NHE3, simultaneous DA(2) agonist synergistically enhances the effect of DA(1). Decreased surface NHE3 antigen, caused by stimulation of NHE3 endocytosis, is dependent on intact functioning of the GTPase dynamin and involves increased binding of NHE3 to the adaptor protein AP2. DA-stimulated NHE3 endocytosis can be blocked by pharmacologic or genetic protein kinase A inhibition or by mutation of two protein kinase A target serines (Ser-560 and Ser-613) on NHE3. We conclude that one mechanism by which DA induces natriuresis is via protein kinase A-mediated phosphorylation of proximal tubule NHE3 leading to endocytosis of NHE3 via clathrin-coated vesicles.

1 August 2015 in Kidney International
Verified
Journal Article
Open access
PDF file
NPNicolas Pallet
Nicolas Pallet
IMIadh Mami
Iadh Mami
CSCaroline SCHMITT
Caroline SCHMITT
Zoubida KarimZoubida Karim
Zoubida Karim
AFArnaud François
Arnaud François
AKAlexandre Karras
Alexandre Karras
Acute intermittent porphyria (AIP) is a genetic disorder of the synthesis of heme caused by a deficiency in hydroxymethylbilane synthase (HMBS), leading to the overproduction of the porphyrin precursors δ-aminolevulinic acid and porphobilinogen. The aim of this study is to describe the clinical and biological characteristics, the renal pathology, and the cellular mechanisms of chronic kidney disease associated with AIP. A total of 415 patients with HMBS deficiency followed up in the French Porphyria Center were enrolled in 2003 in a population-based study. A follow-up study was conducted in 2013, assessing patients for clinical, biological, and histological parameters. In vitro models were used to determine whether porphyrin precursors promote tubular and endothelial cytotoxicity. Chronic kidney disease occurred in up to 59% of the symptomatic AIP patients, with a decline in the glomerular filtration rate of ~1 ml/min per 1.73 m2 annually. Proteinuria was absent in the vast majority of the cases. The renal pathology was a chronic tubulointerstitial nephropathy, associated with a fibrous intimal hyperplasia and focal cortical atrophy. Our experimental data provide evidence that porphyrin precursors promote endoplasmic reticulum stress, apoptosis, and epithelial phenotypic changes in proximal tubular cells. In conclusion, the diagnosis of chronic kidney disease associated with AIP should be considered in cases of chronic tubulointerstitial nephropathy and/or focal cortical atrophy with severe proliferative arteriosclerosis.

14 September 2015 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JDJean‐Christophe Deschemin
Jean‐Christophe Deschemin
MNMarie‐Louise Noordine
Marie‐Louise Noordine
ARAude Remot
Aude Remot
AWAlexandra Willemetz
Alexandra Willemetz
CAClement Afif
Clement Afif
GAËL NICOLASGAËL NICOLAS
GAËL NICOLAS
The amount of iron in the diet directly influences the composition of the microbiota. Inversely, the effects of the microbiota on iron homeostasis have been little studied. So, we investigate whether the microbiota itself may alter host iron sensing. Duodenal cytochrome b and divalent metal transporter 1, involved in apical iron uptake, are 8‐ and 10‐fold, respectively, more abundant in the duodenum of germ‐free (GF) mice than in mice colonized with a microbiota. In contrast, the luminal exporter ferroportin is 2‐fold less abundant in GF. The overall signature of microbiota on iron‐related proteins is similar in the colon. The colonization does not modify systemic parameters as plasma transferrin saturation (20%), plasma ferritin (150 ng/L), and liver (85 μg/g) iron load. Commensal organisms ( Bacteroides thetaiotaomicron VPI‐5482 and Faecalibacterium prausnitzii A2‐165) and a probiotic strain ( Streptococcus thermophilus LMD‐9) led to up to 12‐fold induction of ferritin in colon. Our data suggest that the intestinal cells of GF mice are depleted of iron and that following colonization, the epithelial cells favor iron storage. This study is the first to demonstrate that gut microbes induce a specific iron‐related protein signature, highlighting new aspects of the crosstalk between the microbiota and the intestinal epithelium.—Deschemin, J.‐C., Noordine, M.‐L., Remot, A., Willemetz, A., Afif, C., Canonne‐Hergaux, F., Langella, P., Karim, Z., Vaulont, S., Thomas, M., Nicolas, G. The microbiota shifts the iron sensing of intestinal cells. FASEB J. 30, 252‐261 (2016). www.fasebj.org

2 March 2018 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
CSCaroline SCHMITT
Caroline SCHMITT
HLH. Lenglet
H. Lenglet
AYA. Yu
A. Yu
Constance DelabyConstance Delaby
Constance Delaby
ABA. Benecke
A. Benecke
LGL. Gouya
L. Gouya
Background: Acute intermittent porphyria (AIP) is an inherited disorder of haem metabolism characterized by life‐threatening acute neurovisceral attacks due to the induction of hepatic δ‐aminolevulinic acid synthase 1 (ALAS1) associated with hydroxymethylbilane synthase (HMBS) deficiency. So far, the treatment of choice is hemin which represses ALAS1. The main issue in the medical care of AIP patients is the occurrence of debilitating recurrent attacks.Objective: The aim of this study was to determine whether chronic hemin administration contributes to the recurrence of acute attacks.Methods: A follow‐up study was conducted between 1974 and 2015 and included 602 French AIP patients, of whom 46 had recurrent AIP. Moreover, we studied the hepatic transcriptome, serum proteome, liver macrophage polarization and oxidative and inflammatory profiles of Hmbs−/− mice chronically treated by hemin and extended the investigations to five explanted livers from recurrent AIP patients.Results: The introduction of hemin into the pharmacopeia has coincided with a 4.4‐fold increase in the prevalence of chronic patients. Moreover, we showed that both in animal model and in human liver, frequent hemin infusions generate a chronic inflammatory hepatic disease which induces HO1 remotely to hemin treatment and maintains a high ALAS1 level responsible for recurrence.Conclusion: Altogether, this study has important impacts on AIP care underlying that hemin needs to be restricted to severe neurovisceral crisis and suggests that alternative treatment targeting the liver such as ALAS1 and HO1 inhibitors, and anti‐inflammatory therapies should be considered in patients with recurrent AIP.